Biogen To Pay Ionis $1 Billion To Develop Brain Drugs
Their first collaboration, Spinraza, a treatment for a deadly rare disease called spinal muscular atrophy, generated $884 million sales last year, its first on the market.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:BIIB NASDAQ:IONS Source Type: news